ArticleNew microbes and new infections2018
First report of colistin resistance among carbapenem-resistant
Article in New microbes and new infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence, trends, and molecular insights into colistin resistance among gram-negative bacteria in Egypt: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2025Pooled it
- Prevalence of colistin-resistant Enterobacteriaceae isolated from clinical samples in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- The incidence and prevalence of hospital-acquired (carbapenem-resistant)Emerging microbes & infections · 2019Pooled it
- Molecular Characterization of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2026Article
- Colistin-resistance amongJAC-antimicrobial resistance · 2026Review
- Risk Factors for Mortality in Patients Treated with Colistin Monotherapy for Carbapenem-ResistantInfectious diseases & clinical microbiology · 2025Article
- Distribution of carbapenemase-producing and colistin resistant Acinetobacter baumannii isolates in Batna hospitals, Algeria.BMC infectious diseases · 2025Article
- A Systematic Review and Meta-Analysis of Molecular Characteristics on Colistin Resistance ofDiagnostics (Basel, Switzerland) · 2024Review
- Genomic investigation unveils colistin resistance mechanism in carbapenem-resistantMicrobiology spectrum · 2024Article
- Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Epidemiological and genetic characteristics of clinical carbapenem-resistantEmerging microbes & infections · 2022Article
- Molecular Epidemiology of Clinical Carbapenem-ResistantTropical medicine and infectious disease · 2022Article
- Emergence of high colistin resistance in carbapenem resistantFrontiers in pharmacology · 2022Article
- Deciphering Multidrug-Resistant Acinetobacter baumannii from a Pediatric Cancer Hospital in Egypt.mSphere · 2021Article
- Virulence Characteristics of Biofilm-FormingMicroorganisms · 2021Article
- Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of Acinetobacter baumannii to fluoroquinolones.Scientific reports · 2021Article
- Article
- Colistin and Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Molecular survey of aminoglycoside-resistantNew microbes and new infections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.